Analysts expect that Fate Therapeutics Inc (NASDAQ:FATE) will announce sales of $1.02 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Fate Therapeutics’ earnings. The highest sales estimate is $1.03 million and the lowest is $1.00 million. Fate Therapeutics posted sales of $1.03 million in the same quarter last year, which would indicate a negative year over year growth rate of 1%. The business is expected to announce its next quarterly earnings report on Monday, August 14th.

On average, analysts expect that Fate Therapeutics will report full year sales of $1.02 million for the current financial year, with estimates ranging from $3.00 million to $4.11 million. For the next financial year, analysts anticipate that the firm will post sales of $8.48 million per share, with estimates ranging from $4.02 million to $13.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by $0.03. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.04 million. Fate Therapeutics had a negative return on equity of 112.48% and a negative net margin of 740.69%.

Several research firms have recently commented on FATE. Roth Capital set a $8.00 price target on shares of Fate Therapeutics and gave the company a “buy” rating in a research report on Saturday, March 18th. Wedbush reaffirmed an “outperform” rating and set a $7.00 price target on shares of Fate Therapeutics in a research report on Tuesday, May 16th. Zacks Investment Research lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 7th. HC Wainwright reduced their price target on shares of Fate Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, March 20th. Finally, BMO Capital Markets lifted their price target on shares of Fate Therapeutics to $7.00 and gave the company a “buy” rating in a research report on Friday, March 17th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Fate Therapeutics has a consensus rating of “Buy” and an average target price of $5.88.

Institutional investors have recently modified their holdings of the company. FMR LLC increased its position in shares of Fate Therapeutics by 2.0% in the fourth quarter. FMR LLC now owns 4,391,885 shares of the biopharmaceutical company’s stock worth $11,024,000 after buying an additional 84,400 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Fate Therapeutics by 11.6% in the fourth quarter. Renaissance Technologies LLC now owns 209,900 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 21,900 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Fate Therapeutics by 14.1% in the fourth quarter. Franklin Resources Inc. now owns 6,076,879 shares of the biopharmaceutical company’s stock worth $15,084,000 after buying an additional 751,879 shares during the last quarter. Creative Planning increased its position in shares of Fate Therapeutics by 35.3% in the first quarter. Creative Planning now owns 23,000 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6,000 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Fate Therapeutics by 926.7% in the first quarter. Wells Fargo & Company MN now owns 281,111 shares of the biopharmaceutical company’s stock worth $1,279,000 after buying an additional 253,732 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/09/fate-therapeutics-inc-fate-expected-to-announce-quarterly-sales-of-1-02-million.html.

Shares of Fate Therapeutics (NASDAQ:FATE) traded up 1.22% during trading on Friday, hitting $3.33. 54,017 shares of the stock traded hands. The firm’s market cap is $137.87 million. The company has a 50-day moving average of $3.99 and a 200-day moving average of $3.64. Fate Therapeutics has a 52 week low of $1.54 and a 52 week high of $5.68.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fate Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.